Search research articles
Contact Us
Filters
Showing results (51-60 of 182) with videos related to
Page
of 19
Sort By:
Neuromuscular Disorders : NMD
|
February 6, 2026
Spontaneous remission in statin-associated HMGCR-positive immune-mediated necrotizing myopathy after statin withdrawal
Agata A Mossakowski, Daniel Pascale, Yves Allenbach, et al.
Journal of the American Academy of Dermatology
|
August 8, 2020
Response to: Comment on "Systematic retrospective study on 64 patients anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy"
Grégoire Monseau, Océane Landon-Cardinal, Anne-Marie Bouvier, et al.
Rheumatology (Oxford, England)
|
January 13, 2023
Successful outcome under multiple therapy in two cases of anti-MDA5 dermatomyositis with severe cardiomyopathy and interstitial lung disease
Anaïs Roeser, Jérôme Hadjadj, Lola Prat, et al.
Brain Pathology (Zurich, Switzerland)
|
April 24, 2020
Edematous myositis: a clinical presentation first suggesting dermatomyositis diagnosis
Mathilde Duchesne, Sarah Leonard-Louis, Océane Landon-Cardinal, et al.
Neuromuscular Disorders : NMD
|
June 29, 2012
Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis
Yves Allenbach, Olivier Benveniste, Valérie Decostre, et al.
The Journal of Rheumatology
|
December 17, 2018
Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy
Océane Landon-Cardinal, Yves Allenbach, Antoine Soulages, et al.
Autoimmunity Reviews
|
March 3, 2019
CD8+<sub>T-bet+</sub> cells as a predominant biomarker for inclusion body myositis
Gaëlle Dzangué-Tchoupou, Kuberaka Mariampillai, Loïs Bolko, et al.
Archives of Cardiovascular Diseases
|
January 1, 2025
Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design
Joe-Elie Salem, Stephane Ederhy, Lisa Belin, et al.
Rheumatology (Oxford, England)
|
January 13, 2026
Comment on: Eculizumab as rescue therapy in refractory anti-NXP2 dermatomyositis with digestive vasculitis and gastrointestinal perforation: report of two case: Reply
Loraine Combemale, Alexandre-Raphael Wery, Gérôme Bohelay, et al.
The American Journal of Pathology
|
February 17, 2009
Role of regulatory T cells in a new mouse model of experimental autoimmune myositis
Yves Allenbach, Sounkary Solly, Sylvie Grégoire, et al.
Page
of 19
Search research articles
Search
Showing results (51-60 of 182) with videos related to
Sort By:
Page
of 19
Neuromuscular Disorders : NMD
|
February 6, 2026
Spontaneous remission in statin-associated HMGCR-positive immune-mediated necrotizing myopathy after statin withdrawal
Agata A Mossakowski, Daniel Pascale, Yves Allenbach, et al.
Journal of the American Academy of Dermatology
|
August 8, 2020
Response to: Comment on "Systematic retrospective study on 64 patients anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy"
Grégoire Monseau, Océane Landon-Cardinal, Anne-Marie Bouvier, et al.
Rheumatology (Oxford, England)
|
January 13, 2023
Successful outcome under multiple therapy in two cases of anti-MDA5 dermatomyositis with severe cardiomyopathy and interstitial lung disease
Anaïs Roeser, Jérôme Hadjadj, Lola Prat, et al.
Brain Pathology (Zurich, Switzerland)
|
April 24, 2020
Edematous myositis: a clinical presentation first suggesting dermatomyositis diagnosis
Mathilde Duchesne, Sarah Leonard-Louis, Océane Landon-Cardinal, et al.
Neuromuscular Disorders : NMD
|
June 29, 2012
Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis
Yves Allenbach, Olivier Benveniste, Valérie Decostre, et al.
The Journal of Rheumatology
|
December 17, 2018
Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy
Océane Landon-Cardinal, Yves Allenbach, Antoine Soulages, et al.
Autoimmunity Reviews
|
March 3, 2019
CD8+<sub>T-bet+</sub> cells as a predominant biomarker for inclusion body myositis
Gaëlle Dzangué-Tchoupou, Kuberaka Mariampillai, Loïs Bolko, et al.
Archives of Cardiovascular Diseases
|
January 1, 2025
Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design
Joe-Elie Salem, Stephane Ederhy, Lisa Belin, et al.
Rheumatology (Oxford, England)
|
January 13, 2026
Comment on: Eculizumab as rescue therapy in refractory anti-NXP2 dermatomyositis with digestive vasculitis and gastrointestinal perforation: report of two case: Reply
Loraine Combemale, Alexandre-Raphael Wery, Gérôme Bohelay, et al.
The American Journal of Pathology
|
February 17, 2009
Role of regulatory T cells in a new mouse model of experimental autoimmune myositis
Yves Allenbach, Sounkary Solly, Sylvie Grégoire, et al.
Page
of 19